Abbott Laboratories (NYSE:ABT) price target raised to $90.00 by Bank of America

Analyst Ratings For Abbott Laboratories (NYSE:ABT)

Story continues below

Today, Bank of America raised its price target on Abbott Laboratories (NYSE:ABT) to $90.00 per share.

There are 15 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Abbott Laboratories (NYSE:ABT) is Buy with a consensus target price of $81.2563 per share, a potential 0.96% downside.

Some recent analyst ratings include

  • 4/18/2019-Abbott Laboratories (NYSE:ABT) had its Outperform rating reiterated by William Blair
  • 1/24/2019-Abbott Laboratories (NYSE:ABT) had its Hold rating reiterated by BTIG Research
  • On 5/23/2019 Brian J Blaser, Insider, sold 450,062 with an average share price of $75.52 per share and the total transaction amounting to $33,988,682.24.
  • On 5/2/2019 Jared Watkin, Insider, sold 309,429 with an average share price of $78.51 per share and the total transaction amounting to $24,293,270.79.
  • On 4/25/2019 Jaime Contreras, SVP, sold 82,732 with an average share price of $70.00 per share and the total transaction amounting to $5,791,240.00.
  • On 4/23/2019 Stephen R Fussell, EVP, sold 56,000 with an average share price of $76.00 per share and the total transaction amounting to $4,256,000.00.
  • On 4/22/2019 Jaime Contreras, SVP, sold 918 with an average share price of $73.12 per share and the total transaction amounting to $67,124.16.
  • On 4/22/2019 Randel William Woodgrift, Insider, bought 2,000 with an average share price of $73.40 per share and the total transaction amounting to $146,800.00.
  • On 3/20/2019 Joseph J Manning, Insider, sold 5,613 with an average share price of $79.58 per share and the total transaction amounting to $446,682.54.

About Abbott Laboratories (NYSE:ABT)
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Read More…

Recent Trading Activity for Abbott Laboratories (NYSE:ABT)
Shares of Abbott Laboratories closed the previous trading session at 82.01 up +0.060 0.073% with shares trading hands.

An ad to help with our costs